The Double-Dip Economy: When Companies Profit from Disease and Its Cure. It’s the ultimate business model: create the problem, then sell the solution.
In the modern economy, several giant corporations do exactly that—often within the same company. They fuel chronic illnesses through everyday products, then rake in billions treating those same illnesses. It’s not always a conspiracy; it’s just capitalism optimized to the extreme.
Take the obesity pipeline. Food giants like Nestlé, PepsiCo, and Kraft Heinz engineer ultra-processed foods—cereals, snacks, sodas—loaded with sugar, salt, and fat to trigger the brain’s reward centers like drugs. The result: an epidemic of obesity and type 2 diabetes. Fast-forward to the fix: GLP-1 drugs like Ozempic, Mounjaro, and Wegovy, which suppress appetite and melt weight away. The same institutional investors—BlackRock, Vanguard, State Street—hold major stakes in both the junk-food makers and the pharma companies behind the injections. The cycle is seamless: profit from the cause, profit from the cure. Big Tobacco perfected this decades ago. Philip Morris (now Altria) still dominates cigarettes through Marlboro. Meanwhile, they’ve poured money into pharmaceutical divisions and spin-offs developing lung cancer drugs, COPD treatments, and nicotine replacement therapies like Nicorette.
They sell the addiction, then sell the remedy. Bayer offers another textbook case. Through its Crop Science arm, the company is one of the world’s largest producers of pesticides, herbicides, and genetically modified seeds—products tied in studies to cancer, hormonal disruption, and other long-term health risks. At the same time, Bayer’s Pharmaceuticals division is a powerhouse in oncology, selling blockbuster cancer treatments like Nubeqa for prostate cancer. One arm might contribute to the risk; the other profits from treating it. Even Johnson & Johnson fits the pattern. They own major sunscreen brands like Neutrogena and Aveeno—products meant to protect against skin cancer. Yet in 2021, J&J had to recall millions of aerosol sunscreens after tests detected benzene, a known carcinogen.
At the same time, J&J is one of the biggest names in cancer care, with drugs like Darzalex for multiple myeloma and a pipeline full of immunotherapy treatments. Manufacturing flaw or not, the optics are brutal: risk exposure on one side, treatment revenue on the other. The thread tying all these together? No single evil genius is required. It’s just smart, interlocking corporate strategy. When a company—or its largest shareholders—profits from both ends of the health spectrum, the incentives align perfectly. Prevention, regulation, or consumer awareness could disrupt the loop, but so far, the money keeps flowing both ways. In the end, the system isn’t broken. It’s built this way. And until something stronger than profit motive steps in, it’ll keep spinning. If anything, so much money now pours into the system for treatment to various illnesses, a cure may just crash the whole thing down. Thoughts? Stay gold -J